Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
- Conditions
- Epstein-Barr Virus InfectionsHuman Herpes Virus-6 InfectionJC Virus InfectionCytomegalovirus InfectionsAdenovirus InfectionBK Virus Infection
- Interventions
- Biological: Posoleucel (ALVR105)Biological: Placebo
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 451
- Registration Number
- NCT05305040
- Locations
- πΊπΈ
Northside Hospital, Atlanta, Georgia, United States
π§πͺInstitut Jules Bordet and the Childrens Hospital, Bruxelles, Belgium
π§πͺA.Z. Sint-Jan Brugge Oostende AV, Brugge, Belgium
Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 57
- Registration Number
- NCT05179057
- Locations
- πΊπΈ
University of California, Los Angeles (UCLA), Los Angeles, California, United States
πΊπΈHackensack University Medical Center, Hackensack, New Jersey, United States
πΊπΈAnn and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
- Conditions
- Respiratory Tract Viral InfectionsHuman Metapneumovirus (hMPV) InfectionRespiratory Syncytial Viral (RSV) InfectionInfluenza InfectionParainfluenza (PIV) Infection
- Interventions
- Biological: PlaceboBiological: ALVR106
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 17
- Registration Number
- NCT04933968
- Locations
- πΊπΈ
University of Iowa, Iowa City, Iowa, United States
πΊπΈFroedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
πΊπΈUniversity of North Carolina - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
- Conditions
- Cytomegalovirus InfectionsHuman Herpes Virus-6 InfectionAdenovirus InfectionEpstein-Barr Virus InfectionsBK Virus InfectionJC Virus Infection
- Interventions
- Biological: Posoleucel (ALVR105)
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 26
- Registration Number
- NCT04693637
- Locations
- πΊπΈ
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
πΊπΈUniversity of Kansas Hospital, Westwood, Kansas, United States
πΊπΈUniversity of Maryland Medical Center, Baltimore, Maryland, United States
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
- Conditions
- BK Virus NephropathyBK Virus Infection
- Interventions
- Biological: Placebo (visually identical to Posoleucel)Biological: Posoleucel (formerly known as ALVR105) cells
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 61
- Registration Number
- NCT04605484
- Locations
- πΊπΈ
Baylor University Medical Center, Dallas, Texas, United States
πΊπΈCleveland Clinic Foundation, Cleveland, Ohio, United States
πΊπΈIndiana University Hospital, Indianapolis, Indiana, United States
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
- Conditions
- BK Virus InfectionHemorrhagic Cystitis
- Interventions
- Biological: Posoleucel (ALVR105)Biological: Placebo
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 97
- Registration Number
- NCT04390113
- Locations
- πΊπΈ
Northwestern Memorial Hospital, Chicago, Illinois, United States
πΊπΈUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
πΊπΈUniversity of Miami, Miami, Florida, United States
Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)
- Conditions
- CMV Infections
- Interventions
- Biological: Viralym-C
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 10
- Registration Number
- NCT02313857
- Locations
- πΊπΈ
Texas Childrens Hospital, Houston, Texas, United States
πΊπΈThe Methodist Hospital system, Houston, Texas, United States
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
- Conditions
- BK Virus Infection
- Interventions
- Biological: Viralym-B
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- AlloVir
- Registration Number
- NCT02313844
- Locations
- πΊπΈ
The Methodist Hospital system, Houston, Texas, United States
πΊπΈTexas Childrens Hospital, Houston, Texas, United States
Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)
- Conditions
- Adenovirus Infection
- Interventions
- Biological: Viralym-A
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- AlloVir
- Registration Number
- NCT02276820
- Locations
- πΊπΈ
Texas Childrens Hospital, Houston, Texas, United States
πΊπΈThe Methodist Hospital system, Houston, Texas, United States
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
- Conditions
- Infection
- Interventions
- Biological: Multivirus Specific T cells
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 82
- Registration Number
- NCT02108522
- Locations
- πΊπΈ
Houston Methodist Hospital, Houston, Texas, United States
πΊπΈTexas Children's Hospital, Houston, Texas, United States